Resectable Pancreatic Ductal Adenocarcinoma Clinical Trial
Official title:
A Phase II Study of Neoadjuvant FOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma With Tissue Collection
The primary objective of this study is to evaluate the rate of pathologic complete response to neoadjuvant FOLFIRINOX in patients with resectable pancreatic cancer using a tissue collection component.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05518903 -
An Investigational Scan (68Ga-FAPI-46 PET/CT) for the Imaging of Cancer-Associated Fibroblasts in Patients With Localized Pancreatic Ductal Adenocarcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04010552 -
Nalirinox Neo-pancreas RAS Mut ctDNA Study
|
Phase 2 | |
| Enrolling by invitation |
NCT04875325 -
Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy
|
N/A | |
| Recruiting |
NCT05055323 -
A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03970252 -
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
|
Early Phase 1 | |
| Active, not recruiting |
NCT04484909 -
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT02978547 -
The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04481204 -
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
|
Phase 2 |